Bill > HB1114

This bill expands access to HIV prevention medications by allowing pharmacists to prescribe and dispense preexposure prophylaxis (PrEP), a drug used to prevent HIV infection in HIV-negative individuals, and postexposure prophylaxis (PEP), a drug used to prevent HIV infection after a potential exposure. It also mandates that managed care organizations, insurers, and other health plans must cover these HIV prevention drugs without requiring prior authorization, step therapy (where a patient must try a less expensive drug first), or imposing cost-sharing like copayments or deductibles, as long as the drugs are prescribed according to the U.S. Centers for Disease Control and Prevention (CDC) guidelines. Additionally, the bill requires coverage for medically necessary services related to PrEP and PEP, such as HIV testing, pregnancy testing, and follow-up visits, and establishes that these provisions will take effect on January 1, 2027, with other parts of the bill becoming effective on July 1, 2026.

Health and Social Services

https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB1114?ys=2026RS